Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bacterial 50S ribosomal subunit L11–23S rRNA interface is a critical structural and functional component of the GTPase-associated center (GAC) within the prokaryotic ribosome [1.3.3, 1.3.5]. This interface is formed by the interaction of ribosomal protein L11 (uL11) with a highly conserved 58-nucleotide domain of the 23S rRNA, specifically helices H43 and H44 [1.2.1, 1.3.1]. Its primary biological role is to facilitate the binding and activation of essential translation factors, such as elongation factor G (EF-G) and elongation factor Tu (EF-Tu), which are necessary for protein synthesis [1.3.1, 1.3.3]. Specifically, the interface stimulates the ribosome-dependent GTPase activity of these factors, driving the translocation of mRNA and tRNAs [1.3.3, 1.3.5]. This site is the primary target for the thiopeptide class of antibiotics, including thiostrepton and micrococcin, which bind in a cleft between the L11 N-terminal domain and the rRNA [1.2.1, 1.3.1]. By binding here, these drugs stabilize a specific conformation of the ribosome that prevents the necessary transitions for factor turnover or stable factor binding, thereby halting bacterial translation [1.3.1, 1.3.5]. While highly effective in vitro, the clinical utility of drugs targeting this interface has been limited by poor solubility and pharmacokinetic challenges [1.3.1]. Consequently, it remains a significant focus for the development of next-generation antimicrobials designed to overcome these limitations [1.2.1, 1.4.4].
Inhibition of translation elongation by preventing the stable binding and turnover of elongation factors (e.g., EF-G) on the ribosome [1.3.1, 1.3.3].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial 50S ribosomal subunit L11–23S rRNA interface (GAC interface).